Could a common gout drug protect hearts from myocarditis?
NCT ID NCT05855746
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 3 trial tests whether colchicine, an anti-inflammatory drug, can reduce heart scarring and prevent complications in 300 people with acute myocarditis (heart inflammation). Participants receive colchicine or a placebo for six months alongside standard care. The goal is to see if colchicine lowers the risk of heart failure, arrhythmias, and other serious outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Colchicine
- What this could lead to
- If it works, this could provide a simple, low-cost treatment to reduce heart damage and prevent serious complications like heart failure in people with acute myocarditis.
- What could go wrong
- This is a Phase 3 trial, but colchicine may not reduce heart scarring or clinical events. Side effects like diarrhea and nausea are possible, and the benefit over standard care is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut de Cardiologie - APHP Pitié Salpêtrière
RECRUITINGParis, 75013, France
-
Unité de Soins Intensifs Cardiologiques - Hôpital Cardiovasculaire Louis Pradel
RECRUITINGBron, 69029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.